• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

    5/22/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a Water Tower Research Fireside Chat taking place on Thursday, May 29, 2025, at 11:00 a.m. ET.

    The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include:

    • The evolution of interventional psychiatry clinics and the importance of Cybin's partnership with Osmind.
    • Progress of the CYB003 Phase 3 program and the impact of recently announced strategic clinical partnerships and the Thermo Fisher collaboration.
    • Upcoming milestones and timelines.
    • Thoughts on the noise of psychedelics coming out of the FDA.

    To listen to the event, please click here to register for the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page.

    About Cybin

    Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

    With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

    Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250522228359/en/

    Investor & Media Contact:

    Gabriel Fahel

    Chief Legal Officer

    Cybin Inc.

    1-866-292-4601

    [email protected] – or – [email protected]

    Get the next $CYBN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Cybin with a new price target

      Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

      3/13/25 7:34:44 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cybin with a new price target

      HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      11/22/21 6:24:49 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin downgraded by Maxim Group

      Maxim Group downgraded Cybin from Buy to Hold

      11/19/21 8:09:52 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care